0IFK Stock Overview
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 2/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Editas Medicine, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$5.95 |
52 Week High | US$11.79 |
52 Week Low | US$5.89 |
Beta | 2.02 |
1 Month Change | -24.49% |
3 Month Change | -26.72% |
1 Year Change | -26.28% |
3 Year Change | -83.27% |
5 Year Change | -77.62% |
Change since IPO | -83.45% |
Recent News & Updates
Recent updates
Shareholder Returns
0IFK | GB Biotechs | GB Market | |
---|---|---|---|
7D | -9.7% | -0.5% | 0.4% |
1Y | -26.3% | -28.5% | -1.0% |
Return vs Industry: 0IFK exceeded the UK Biotechs industry which returned -28.5% over the past year.
Return vs Market: 0IFK underperformed the UK Market which returned -1% over the past year.
Price Volatility
0IFK volatility | |
---|---|
0IFK Average Weekly Movement | 10.9% |
Biotechs Industry Average Movement | 7.6% |
Market Average Movement | 4.9% |
10% most volatile stocks in GB Market | 11.3% |
10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: 0IFK's share price has been volatile over the past 3 months.
Volatility Over Time: 0IFK's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of UK stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2013 | 265 | Gilmore O’Neill | www.editasmedicine.com |
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia.
Editas Medicine, Inc. Fundamentals Summary
0IFK fundamental statistics | |
---|---|
Market cap | US$478.61m |
Earnings (TTM) | -US$153.22m |
Revenue (TTM) | US$78.12m |
6.1x
P/S Ratio-3.1x
P/E RatioIs 0IFK overvalued?
See Fair Value and valuation analysisEarnings & Revenue
0IFK income statement (TTM) | |
---|---|
Revenue | US$78.12m |
Cost of Revenue | US$177.65m |
Gross Profit | -US$99.53m |
Other Expenses | US$53.69m |
Earnings | -US$153.22m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -1.87 |
Gross Margin | -127.40% |
Net Profit Margin | -196.13% |
Debt/Equity Ratio | 0% |
How did 0IFK perform over the long term?
See historical performance and comparison